| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4319fe3d827bd24add491d4ed90e7692
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2016-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c21df572f16bb797419894a5a6e79135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2473080c0edd40e6b1a2be89c9874d5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19f1ee87417934b51e8b0ce726c8d96d |
| publicationDate |
2017-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2016201644-B2 |
| titleOfInvention |
Detection and treatment of fibrosis |
| abstract |
Methods of treating a subject having fibrosis or at risk of developing fibrosis by administering a Cadherin- 11 (CD-H 11) antagonist are provided. The treatment may be administered to subjects with dermal or non-dermal fibrosis, including lung, liver or kidney fibrosis or idiopathic pulmonary fibrosis. Methods of assessing the levels of CDH1 1 in a subject and determining fibrosis or risk of developing fibrosis are also provided. |
| priorityDate |
2010-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |